1233979-32-2

Upstream product

• 1233979-42-4 6,6'-dihydroxy-5,5'-dimethoxy-N,N'-dimethylbiphenyl-2,2'-dicarboxamide 

Downstream Products

• 1233979-33-3 6-{2-[(3-chloro-4-fluorophenyl)amino]-2-oxoethoxy}-5,5'-dimethoxy-N,N'-dimethyl-6'-(2-morpholin-4-ylethoxy)biphenyl-2,2'-dicarboxamide 

Relevant academic research and scientific papers

Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents

Antiangiogenic therapy might represent a new promising anticancer therapeutic strategy. Taspine can significantly inhibit cell proliferation of human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor-165, which is crucial for angiogenesis. In this study, a series of novel taspine derivatives were synthesized and screened for in vitro anticancer and antiangiogenesis activities. The majority of the derivatives demonstrated a moderate degree of cytotoxicity against human cancer cell lines. One of them (14) exhibited much better antiproliferative activity against CACO-2 (IC 50 = 52.5 μM) and ECV304 (IC50 = 2.67 μM) cells than taspine did. Some of them were also effective in antiproliferative assays against HUVECs. The in silico estimate of solubility of title compounds were higher than that of taspine.